Aldeyra Therapeutics (ALDX) Total Current Liabilities (2013 - 2026)
Aldeyra Therapeutics' (ALDX) quarterly Total Current Liabilities came in at $24.3 million in Q1 2026, up 70.28% YoY from $14.3 million in Q1 2025, and down 12.52% on a QoQ basis from $27.8 million in Q4 2025.
Aldeyra Therapeutics (ALDX) Total Current Liabilities (2013 - 2026) Analysis & Trends
Aldeyra Therapeutics (ALDX) has 14 years of Total Current Liabilities data on file, last reported at $24.3 million in Q1 2026.
- Quarterly Total Current Liabilities rose 70.28% year-over-year to $24.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $24.3 million (up 70.28% YoY) and the FY2025 annual result came in at $27.8 million, up 49.5% from the prior year.
- Total Current Liabilities fell to $24.3 million in Q1 2026, from $27.8 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $29.5 million in Q2 2025 to a low of $14.3 million in Q1 2025.
- A 5-year average of $21.0 million and a median of $21.6 million in 2023 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Current Liabilities surged 119.23% — and 2025, when it tumbled 34.1%.
- Tracing ALDX's Total Current Liabilities over 5 years: stood at $15.4 million in 2022, then jumped by 44.92% to $22.3 million in 2023, then retreated by 16.43% to $18.6 million in 2024, then soared by 49.5% to $27.8 million in 2025, then decreased by 12.52% to $24.3 million in 2026.
- The last three Total Current Liabilities figures came in at $24.3 million (Q1 2026), $27.8 million (Q4 2025), and $28.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.51 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 438.74 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 630.93 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 2.49 Bn |
| 10 | Aldeyra Therapeutics | 91.08 Mn | 91.08 Mn | - | 9.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.66 Mn |
| Mar 31, 2026 | 24.33 Mn |
| Dec 31, 2025 | 27.81 Mn |
| Sep 30, 2025 | 28.48 Mn |
| Jun 30, 2025 | 29.53 Mn |
| Mar 31, 2025 | 14.29 Mn |
| Dec 31, 2024 | 18.60 Mn |
| Sep 30, 2024 | 17.15 Mn |
| Jun 30, 2024 | 27.59 Mn |
| Mar 31, 2024 | 21.68 Mn |
| Dec 31, 2023 | 22.26 Mn |
| Sep 30, 2023 | 21.62 Mn |
| Jun 30, 2023 | 15.61 Mn |
| Mar 31, 2023 | 16.01 Mn |
| Dec 31, 2022 | 15.36 Mn |
| Sep 30, 2022 | 24.20 Mn |
| Jun 30, 2022 | 16.24 Mn |
| Mar 31, 2022 | 16.35 Mn |
| Dec 31, 2021 | 11.77 Mn |
| Sep 30, 2021 | 11.94 Mn |